Related Experiment Video
Updated: Feb 4, 2026

Isolation and Transplantation of Hematopoietic Stem Cells HSCs
Published on: February 25, 2007
Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation
Catharina Schuetz1, Manfred Hoenig1, Despina Moshous2,3
1Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
Abstract:
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells
Half-life of a Reaction
Induced Pluripotent Stem Cells
Characteristics of Life
The Angiosperm Life Cycle

